Venous Thromboembolism

Preoperative blood transfusion, arthrotomy, femur fracture and patients aged 16 to 18 years are risk factors for venous thromboembolism among pediatric orthopedic surgical patients, results showed.

For patients with suspected pulmonary embolism, diagnostic strategies to rule out PE that apply adapted D-dimer thresholds were safe and efficient, even in high-risk patients.

FDA approved rivaroxaban in tablet form and as an oral suspension to treat and reduce the risk for recurrence of venous thromboembolism among certain populations of children.

In patients with rheumatoid arthritis, risk of venous thromboembolism was higher in those taking 10 mg of tofacitinib twice a day compared to 5 mg or TNF inhibitors, according to findings from the ORAL Surveillance study.

Patients with psoriatic disease had a higher incidence of venous thromboembolism and peripheral vascular disease, according to a study.

A 2019 European Medicines Agency warning that tofacitinib could increase risk for venous thromboembolism in patients with rheumatoid arthritis did not affect characteristics of patients starting the drug since then, according to a study.

In patients who underwent knee arthroplasty, milvexian, a novel factor XIa inhibitor, was effective at preventing venous thromboembolism and was linked to a low rate of bleeding, researchers reported.

Due to nonspecific symptoms and a wide variety of therapeutic options, diagnosis and treatment of pulmonary embolism can be challenging.

Therapeutic-dose low-molecular-weight heparin decreased the likelihood of blood clots and death compared with standard of care among patients hospitalized with COVID-19, according to study results published in JAMA Internal Medicine.

World Thrombosis Day is observed Oct. 13.